Allergy & Immunology Doctors in Bellevue, WA Accepting Medicare

6 Allergy & Immunology doctors found. Showing 1 - 6

Dr. Britton Lee Georges, M.D. Allergy & Immunology - Allergy Medicare: Not Enrolled in Medicare Practice Location: 1515 116th Ave Ne, Suite 207, Bellevue, WA 98004 Phone: 425-454-3329    Fax: 425-454-4390

Garrison H Ayars, MD Allergy & Immunology - Allergy Medicare: Not Enrolled in Medicare Practice Location: 1200 112th Ave Ne, Suite C210, Bellevue, WA 98004 Phone: 425-454-2191    Fax: 425-453-1270

Kevin T Dooms, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1200 112th Ave Ne, Suite C210, Bellevue, WA 98004 Phone: 425-454-2191    Fax: 425-453-1270

Dr. Jon E Welch, M. D. Allergy & Immunology - Allergy Medicare: Accepting Medicare Assignments Practice Location: 2320 130th Ave Ne, Ste 220, Bellevue, WA 98005 Phone: 425-777-7486

Charles G Jackson, MD Allergy & Immunology - Allergy Medicare: Not Enrolled in Medicare Practice Location: 1200 112th Ave Ne, Suite C-210, Bellevue, WA 98004 Phone: 425-454-2191    Fax: 425-453-1270

Dr. John William Knutson, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 1200 112th Ave Ne Ste B250, Bellevue, WA 98004 Phone: 206-386-9500    Fax: 206-386-9605

News Archive

Helix BioMedix announces additional funding of $2.9M through convertible promissory notes

Helix BioMedix, Inc., a developer of bioactive peptides, announced additional funding in the amount of $2.9 million through convertible promissory notes. The company also announced the addition of Lawrence Blake Jones to its board of directors.

FDA joins Tox21 collaboration for improved chemical screening

The U.S. Environmental Protection Agency (EPA), the National Institute of Environmental Health Sciences National Toxicology Program (NTP) and the National Institute of Health Chemical Genomics Center (NCGC) welcome the U.S. Food and Drug Administration (FDA) to the Tox21 collaboration. The Tox21 collaboration merges federal agency resources (research, funding and testing tools) to develop ways to more effectively predict how chemicals will affect human health and the environment. The collaboration was established in 2008 to develop models that will be able to better predict how chemicals will affect humans. FDA will provide additional expertise and chemical safety information to improve current chemical testing methods.

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

Astellas Pharma extends tender offer for OSI Pharmaceuticals

Astellas Pharma Inc. announced today that it has extended its all-cash tender offer for $52 per share for all of the currently outstanding shares of common stock (including the associated stock purchase rights) of OSI Pharmaceuticals, Inc. to 5:00 p.m. New York City time on Monday, May 17, 2010, unless further extended.

Read more Medical News

› Verified 3 days ago